Search Results
Jul 27, 2026, 07:30 ET Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565
received a clinical trial notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) approving the Investigational New Drug (IND) application for its novel dual-payload ADC drug, SKB565, for the treatment of advanced solid
More news about: Kelun-Biotech
Jul 27, 2026, 07:00 ET Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million
Avilar Therapeutics, a company RA Capital helped establish later that year, used confidential information from those discussions to build a competing drug development program instead of pursuing a partnership with Yale.Biohaven licensed the MODA platform from Yale to develop and commercialize
More news about: Biohaven Ltd.
Jul 27, 2026, 06:59 ET Metal Organic Frameworks Market worth $2.22 billion by 2031 - Exclusive Report by MarketsandMarkets™
pharmaceutical industries. Although gas storage and separation applications account for the largest share of the market today, biomedical applications such as drug delivery have been identified as the fastest-growing area. Leading chemical manufacturers have made extensive investments in research and development
More news about: MarketsandMarkets
Jul 27, 2026, 06:10 ET Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model
proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides,
More news about: Ascletis Pharma Inc.
Jul 27, 2026, 06:10 ET 歌禮宣布每月一次皮下注射GLP-1R/GIPR/GCGR三靶點激動劑多肽ASC37在飲食誘導肥胖小鼠模型中展現出優越的減重效果
一家全價值鏈整合型生物技術公司，聚焦有望成為治療代謝疾病同類最佳（best-in-class）和同類首創（first-in-class）藥物的開發和商業化。利用公司專有的基於結構的AI輔助藥物發現（Artificial Intelligence-assisted Structure-Based Drug Discovery，AISBDD）、超長效藥物開發平台（Ultra-Long-Acting Platform，ULAP）技術以及口服多肽遞送增強技術（Peptide Oral Transport ENhancement Technology，POTENT），歌禮已自主研發多款小分子和多肽候選藥
More news about: 歌禮製藥有限公司
Jul 27, 2026, 06:00 ET IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers
including approximately 1,400-fold selective MTA-PRMT5 cooperative binding versus SAM-PRMT5 cooperative binding, lack of brain penetrance, and favorable drug-like properties intended to maximize its therapeutic window as both a monotherapy agent and in combination. We are well positioned to have the industry's
More news about: IDEAYA Biosciences, Inc.
Jul 27, 2026, 06:00 ET Bambusa Therapeutics Reports Potentially Transformative Preliminary Proof-of-Concept Results for BBT001 in Atopic Dermatitis, Reinforcing Its Best-in-Disease Potential
dosing as infrequently as once every three months.Low immunogenicity. BBT001 demonstrated a low incidence of treatment-emergent anti-drug antibodies, with low titers and no apparent evidence of neutralizing activity, consistent with prior findings in healthy volunteers.Table
More news about: Bambusa Therapeutics
Jul 27, 2026, 05:02 ET Harbour BioMed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D Consortium
therapeutic areas. Harbour BioMed will leverage its globally leading Harbour Mice® fully human antibody technology platform and AI-enabled drug discovery capabilities to drive the discovery and optimization of antibody candidates together with Sinopharm.
More news about: Harbour BioMed
Jul 27, 2026, 00:01 ET The9 Posts Record Quarterly Profit; Expects Sequential Growth Through 2026
continues to explore emerging opportunities across AI-empowered industries and the broader digital ecosystem, including an equity stake in AI-driven drug discovery company NYB, building a multi-engine business positioned at the frontier of AI and the new economy, reshaping how value is created and shared.Forward-Looking
More news about: The9 Limited
Jul 27, 2026, 00:00 ET The9 Names George Lai Chief Executive Officer
continues to explore emerging opportunities across AI-empowered industries and the broader digital ecosystem, including an equity stake in AI-driven drug discovery company NYB, building a multi-engine business positioned at the frontier of AI and the new economy, reshaping how value is created and shared.
More news about: The9 Limited
Jul 24, 2026, 18:37 ET Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28
for perioperative pain management in laparoscopic surgery; Valor™ transdermal delivery of peptides; biomechanical molecular instruction technology for drug delivery; and localized delivery of oncology therapies for pancreatic cancer. Vector is currently focused on commercializing the first two verticals
More news about: Vector Sciences & Therapeutics
Jul 24, 2026, 17:25 ET American Regent, Inc. Issues Voluntary Nationwide Recall of One Lot of Papaverine Hydrochloride Injection, USP 60 mg/ 2 mL Due to the Presence of Visible Particulate Matter
provider.Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.
More news about: American Regent, Inc.
Jul 24, 2026, 16:15 ET Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
development continue; (ii) rezpegaldesleukin, NKTR-0165, NKTR-0166 and NKTR-422 are investigational agents and continued research and development for these drug candidates is subject to substantial risks, including negative safety and efficacy findings in future clinical studies (notwithstanding positive findings
More news about: Nektar Therapeutics
Jul 24, 2026, 14:00 ET FDA Approves TYLENOL® with Naproxen, the First and Only Over-the-Counter Fixed-Dose Combination of Acetaminophen (650 mg) and Naproxen Sodium (220 mg)
a non-steroidal anti-inflammatory drug, naproxen sodium – starting to work in under 30 minutes and delivering effective pain relief for 12 hours.How does TYLENOL® with Naproxen work? Acetaminophen is believed to work quickly to reduce pain signals. Naproxen sodium, a non-steroidal anti-inflammatory drug (NSAID),
More news about: Kenvue Inc.
Jul 24, 2026, 12:52 ET ActivatedYou by Maggie Q Launches Vital Strength, ActivatedYou's First Muscle-Supporting, Creatine Supplement: A Performance Formula for Lean Muscle, Recovery, and Total-Body Resilience
†These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.Press Contact:
More news about: ActivatedYou
Jul 24, 2026, 12:46 ET Gundry MD® Daily Weight Advantage™ Named Best Weight Management Supplement of 2026 by NutraIngredients-USA
✝ These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.*All individuals
More news about: Gundry MD
Jul 24, 2026, 11:00 ET Timeshifter Marks Circadian Awareness Day (24/7) with "Why Timing Matters in Healthcare"
Real-world examples included older adults given a morning flu vaccine producing more antibodies than those vaccinated in the afternoon; a common cholesterol drug working better when taken at night; and heart-valve surgery patients treated in the afternoon suffering less heart-muscle injury than those operated
More news about: Timeshifter Inc.
Jul 24, 2026, 10:35 ET Truth Initiative Brings National, Award-Winning Behavior-Change Expertise to Ohio Cannabis Education Efforts
with free, digital curricula for students in 8-12th grade addressing cannabis use and to help young people better understand and navigate prescription drug misuse.The organization has received hundreds of major awards across, including more than 50 Effie Awards, including two Grand Effies. Truth
More news about: Truth Initiative
Jul 24, 2026, 10:13 ET NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
objectives and milestones, including approval of the Company's product candidates and potential commercialization; challenges inherent to the launch of new drug products, if approved; risks related to the Company's reliance on third parties; and other important factors, any of which could cause the Company's
More news about: Menarini Industrie Farmaceutiche Riunite
Jul 24, 2026, 10:00 ET CIRCA Scientific Appoints Jack Darby as Chief Executive Officer to Accelerate Commercial Expansion of Cardiovascular Access Portfolio
Darby joins CIRCA as the Company enters an important new phase of commercial growth following recent U.S. Food and Drug Administration (FDA) clearances of the CrossWise™ RF Transseptal Access System and the PeriCross™ Epicardial Access Kit. Together with CIRCA's established
More news about: CIRCA Scientific, Inc.
Jul 24, 2026, 09:10 ET A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed
missing piece in AI drug discovery: not a bigger model, but the connected biological context that models need to reason over.Key TakeawaysMindWalk Holdings Corp. (NASDAQ: HYFT) gave the first public demonstration of ReefIQ™, its biological context layer for AI drug discovery, running
More news about: American News Group
Jul 24, 2026, 09:00 ET ELEPHAS PRESENTS NEW DATA SHOWING elive™ PLATFORM MEASURES CYTOTOXICITY ENDPOINTS IN TARGETED THERAPIES, EXTENDING PLATFORM'S POWER
announced new data at the American Association for Cancer Research Drug Discovery and Development (AACR D3) conference. The data show that the elive platform, already shown to measure response to immune checkpoint inhibitors
More news about: Elephas
Jul 24, 2026, 08:30 ET Ridgetech Strengthens Pharmaceutical Ecosystem Leadership with Vice-President Role in Zhejiang Biomedical Association
supply chain network.Policy Context: The National Drug Traceability ReformZhejiang Province is among China's pioneering regions in advancing comprehensive drug traceability reform. Through the implementation of full-variety drug traceability code scanning, Zhejiang has taken a leading
More news about: Ridgetech, Inc.
Jul 24, 2026, 08:30 ET Roche receives FDA clearance for the cobas® BV/CV assay, enabling fast and highly accurate vaginitis diagnosis
July 24, 2026 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its cobas® BV/CV (Bacterial vaginosis/Candida vaginitis) assay. This molecular diagnostic
More news about: Roche
Jul 24, 2026, 08:00 ET Jubilant Biosys Brings Together Global Biotech Leaders to Advance the Future of Healthcare Innovation at 2nd EDGE Innovation Forum
/PRNewswire/ -- Jubilant Biosys, an integrated drug discovery and development partner, convened the 2nd EDGE Innovation Forum in San Diego on July 23. The forum brought together leading biotechnology founders, venture capital leaders, pharmaceutical executives, and drug discovery experts from around the world
More news about: Jubilant Biosys Limited